Quarterly ResultJul 16, 2026, 04:03 PM
DBV Technologies Q2 Net Loss $50.4M; VIASKIN® Peanut Patch BLA in Q3
AI Summary
DBV Technologies reported its Q2 and H1 2026 financial results, with a net loss of $50.4 million for the second quarter and $98.0 million for the half-year. The company maintains a strong cash position of $174.9 million, providing funding into Q3 2027. DBV anticipates submitting the Biologics License Application (BLA) for its VIASKIN® Peanut Patch in children aged 4-7 years during the third quarter of 2026, following continued engagement with the FDA. Operational highlights include progress in clinical trials and investments in commercial readiness for a potential product launch.
Key Highlights
- Reported cash and cash equivalents of $174.9 million as of June 30, 2026, funding into Q3 2027.
- Anticipates BLA submission for VIASKIN® Peanut Patch (4-7 years) in Q3 2026, following productive FDA engagement.
- Net loss for Q2 2026 was $50.4 million, and $98.0 million for H1 2026.
- Net loss per share for H1 2026 improved to $(0.23) from $(0.58) in H1 2025 due to equity financing.
- R&D expenses increased to $64.6 million for H1 2026, driven by clinical trials and BLA preparation.
- SG&A expenses rose by $20.7 million for H1 2026, reflecting U.S. commercial infrastructure build-out.
- Recruitment closed for COMFORT Toddlers study; THRIVE study initiated for infants aged 6-12 months.
Price Impact
More from DBVT